Waldenströ m macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to firstline chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenströ m an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenströ m macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.
INTRODUCTION
In 1944, Jan Gosta Waldenströ m 1 first described two patients with oronasal bleeding, lymphadenopathy, anemia, thrombocytopenia, elevated sedimentation rate and BM showing predominantly lymphoid cells. Waldenströ m macroglobulinemia is a lymphoplasmaproliferative disorder with a monoclonal pentameric IgM. The BM and lymph nodes are infiltrated with pleomorphic B-lineage cells at different stages of maturation. The BM pattern is predominantly intertrabecular. 2 The median age at diagnosis is 64 years (range, 30--88 years), and 53% of patients are aged 65 years or younger. 3 The median survival from the time of diagnosis is 6.4 years, and the median disease-specific survival is 11.2 years. Many patients have a presymptomatic phase; although they fulfill all other criteria for the diagnosis, they do not require therapy. 4 The cells express pan B-cell markers and are usually positive for CD5, CD20, CD10 and CD23 and are negative for CD3 and CD103. 5 The 6q deletion is present in 42% of patients and is associated with an adverse prognosis. 6 Waldenströ m pathophysiology is divided into morbidities caused by the tumor mass and those caused by the monoclonal protein (Table 1) . 2 The disease is incurable with current therapies. This review is designed to summarize the data in support of autologous and allogeneic stem cell transplants in the management of this lymphoma.
WHY CONSIDER A TRANSPLANT IN THIS DISEASE?
A critical reader of the literature may question why a stem cell transplant should be considered at all, given the wide number of new regimens available for the treatment of this disorder. Rituximab, 7 chlorambucil, 8 alkylating agent combinations, 9 R-CHOP (rituximab, CY, doxorubicin (hydroxydaunorubicin), VCR (Oncovin) and prednisone) 10, 11 and purine nucleoside analogs 12, 13 have all produced high response rates, and many of the responses are durable. Recently, bortezomib 14, 15 and bendamustine 16 have both been shown to be highly active in the management of Waldenströ m macroglobulinemia. Investigations into the use of the mTOR inhibitor everolimus 17 have shown it to be useful in heavily pretreated Waldenströ m macroglobulinemia. Under active investigation, AKT inhibitors such as perifosine 18 have been investigated for their activity as have the immunomodulatory agents thalidomide and lenalidomide. 19 Histone deacetylase inhibitors are also considered active agents. 20 Given the widespread availability of multiple low-intensity chemotherapeutic regimens, why would one consider stem cell transplant to treat this disorder?
Alkylating agents and purine nucleoside analogs are not benign agents. There appears to be an increased incidence of malignant transformation and myelodysplasia in macroglobulinemia patients treated with nucleoside analogs. 21 Therapy-related myelodysplasia following fludarabine therapy has also been reported. 22 In an early trial of alkylating agents in the treatment of macroglobulinemia, acute leukemia or refractory anemia developed in 4 of 46 patients. 8 Peripheral neuropathy, secondary to bortezomib, has been reported in 47% of patients with multiple myeloma. 23 Recovery, if it occurs, can take 41 1 2 years. 24 These short-and longterm toxicities justify looking at autologous stem cell transplant as an alternate modality.
The gene transcription profile of Waldenströ m macroglobulinemia more closely resembles that of chronic lymphatic leukemia than that of multiple myeloma. 25 The value of stem cell transplant for chronic lymphatic leukemia is well documented. 26, 27 Waldenströ m macroglobulinemia lacks the typical adverse cytogenetics 28 that are associated with diseases in which autologous stem cell transplant is regularly contemplated such as multiple myeloma. At diagnosis, À17p deletion is distinctly uncommon. 29 Waldenströ m macroglobulinemia is a far less kinetically active malignancy than multiple myeloma. 30, 31 The favorable genetics of macroglobulinemia and the low proliferative rate suggest that a single course of myeloablative therapy can produce a deep and durable response since the cells lack drug resistance mutations and are unlikely to regrow in the near term. 32 As a consequence, one could anticipate better outcomes using autologous stem cell transplant in Waldenströ m than in multiple myeloma. This is borne out by the available literature we review.
AUTOLOGOUS STEM CELL TRANSPLANT
Single-center experience If stem cell transplant is to be considered second-line therapy for Waldenströ m, the choice of first-line therapy becomes critical. The use of fludarabine impedes peripheral blood stem cell mobilization in low-grade lymphoma and chronic lymphatic leukemia. 33 Moreover, purine nucleoside analogs need to be avoided in the induction therapy of these patients. Treatment recommendations from the Fourth International Workshop on Waldenströ m Macroglobulinemia 34 and from Mayo Clinic mSMART guidelines 4 specifically advise avoidance of purine nucleoside analogs if the patient is a candidate for an autologous transplant. 34 The ability to successfully mobilize stem cells is directly related to the number of lines of prior chemotherapy that have been administered. Therefore, consideration of stem cell collection before patients have been exposed to multiple regimens is well advised. 35 The concept of 'rainy day' autologous stem cell harvest has been supported by other groups; harvesting and cryopreserving stem cells for later infusion have been used in AML and chronic myeloid leukemia, multiple myeloma and follicular lymphomas. 36 Stem cell transplant has been used in the initial therapy of patients with Waldenströ m macroglobulinemia. 37 This report describes five patients; all five patients achieved a partial response. None achieved more than a very good partial response (490% reduction in IgM protein). Since anemia is such a common accompaniment of the disease, one of the end points often used for response is a rise in hemoglobin. In these five patients, the median increase in hemoglobin was 3.8 g/dL. Melphalan, 200 mg/m 2 , was administered for conditioning, and mobilization was achieved with growth factor plus chemotherapy. The reported data, however, do not provide a median response duration or the median duration of relapse-free survival. The majority of patients reported received stem cell transplants after progression from initial therapy.
As is typical, the first experience with an autologous transplant in a patient with Waldenströ m macroglobulinemia was a single case report. On a regimen of high-dose melphalan, a 50-year-old man achieved CR that was ongoing at 12 months. 38 High-dose chemotherapy with peripheral blood stem cell support was reported in a series of six patients; their median age was 51 years. 39 Four patients had relapsed disease and two patients received transplants after only minimal induction therapy. In two patients with extensive fludarabine exposure, mobilization of stem cells failed. All patients were conditioned with melphalan chemotherapy or melphalan and TBI. All patients achieved a partial response, with one complete response. Five patients were alive at the time of the report and four patients were event free at 2, 12, 15 and 52 months. This study first established the efficacy of high-dose therapy for Waldenströ m macroglobulinemia.
MD Anderson Cancer Center reported their first experience on four patients who received transplants. 40 All had refractory or relapsed disease. One of the four patients died in the first 100 days, two patients achieved a partial response that lasted 26 and 108 months and one patient who had a partial response relapsed after 31 months and died at 37 months.
In another study, 41 eight patients with Waldenströ m macroglobulinemia received melphalan-based chemotherapy with no treatment-related mortality. There were seven partial responses and one complete response; five of these eight patients were alive and relapse free from 6 to 77 months after treatment.
An update of the Little Rock, Arkansas, experience reported 22 patients with symptomatic Waldenströ m; tandem transplant was used in six patients. 42 Conditioning was done with melphalan in 20 and BEAM (carmustine (BCNU), etoposide, cytarabine (ara-C) and melphalan) in two patients. At a median follow-up of 32 months, 18 were alive and 16 were progression free. There were 10 complete responses, 9 partial responses and 2 less than partial responses.
Registry and cooperative group experience The first 24 reported patients who received transplants for Waldenströ m were described in six individual reports. 43 All received conditioning with either melphalan or CY, and 9 also received TBI. None of these patients were conditioned with BEAM. In this heavily pretreated population, responses were seen in 23 of the 24 patients, with 1 early death; 9 of the 23 evaluable patients achieved a complete response. 43 The first report of the French experience with transplants to treat Waldenströ m was published in 2003. 44 Waldenströ m patients underwent 19 autologous transplants. The median time between diagnosis and transplant was 36 months. High-dose therapy yielded a 95% response rate. With a median follow-up of 18 months, 12 patients were alive at 10--81 months and 8 patients were relapse free at 10--34 months. Treatment-related mortality was 6%.
A review of the database at the Center for International Blood and Marrow Transplant Research was undertaken between 1986 and 2002. 45 Ten patients received an autologous transplant. These patients had a median age of 56 years, and only 1 had a hemoglobin level o10 g/dL, suggesting relatively early or chemosensitive disease. Eight of the 10 had previous cytotoxic chemotherapy; 1 was previously untreated. Marrow infiltration at the time of diagnosis was only 20%. All these characteristics suggest that this was a highly favorable group. Seven of the 10 received peripheral blood stem cells, and 3 received BM stem cells. The median follow-up of survivors was 63 months. The cumulative instance of nonrelapse mortality following stem cell transplant was 11% (1 of 9 evaluable recipients). The PFS at 3 years, however, was 65%, and the OS at 3 years was 70%, which is respectable compared with relapse-free survival using standard chemotherapy in patients with relapsed or refractory disease. At the time of the report, 4 of the 10 patients had died because of primary disease, infection, vascular complications or a second malignancy. These small numbers distributed among seven different centers suggest that stem cell transplant is feasible, has low treatment-related mortality and is capable of producing durable responses. The largest registry study of transplants for Waldenströ m derives from the European Bone Marrow Transplant Registry, which reviewed 201 patients with Waldenströ m macroglobulinemia. 46 These results represent realistic outcomes seen in nonacademic medical centers. The median age of the patients was 53 years. The median time from diagnosis to transplant was 18 months, with a median of two lines of prior therapy. Only 14% had relapsed or refractory disease. The remainder were chemotherapy sensitive, to some degree, to their last line of therapy. Forty-four percent of patients received BEAM, CY or melphalan, with TBI in 28%, high-dose melphalan in 14% and other treatment in 14%. Eighty-eight percent received peripheral blood stem cells, with a median follow-up of 26 months. Fifty-six percent of patients were alive and free of disease at the time of the report. Thirty-six percent relapsed after a median of 14 months. At the time of the report, 18% had died from disease progression and 8% from regimen toxicity. The nonrelapse mortality was 6% at 1 year. The actuarial OS was 86% at 1 year, 75% at 3 years and 61% at 5 years. The probability of relapse at 3 and 5 years was 38 and 55%, respectively. PFS at 1, 3 and 5 years was 74, 54 and 33%, respectively. The ability of a stem cell transplant to produce responses with a median duration of 3 years strongly supports the use of this technique if the treatment-related mortality can be anticipated to be low.
The updated French experience on Waldenströ m macroglobulinemia derived from 18 participating institutions has also been reported. 47 Autologous transplant was performed in 32 patients, with a median age of 56 years. Conditioning was done with a BEAM regimen in 13 patients, melphalan and TBI in 9 patients, TBI and CY in 7 patients and other in 3 patients. The median follow-up was 45 months; at the time of the report, 56% of patients had relapsed and 44% had died. Of the 14 deaths, 10 were due to disease progression and 4 were treatment related. The median EFS was 32 months, and the 1-, 3-and 5-year survival was 87, 77 and 58%, respectively. The TRM was 12.5%. Thus, autologous stem cell transplant can achieve long-term responses even in heavily pretreated patients.
The British Society of Blood and Marrow Transplantation reviewed stem cell transplantation in lymphoplasmacytic lymphoma. 48 Eighteen patients were identified with a median age of 50 years. Nine patients received high-dose chemotherapy with autologous peripheral blood stem cells. Seven of the nine were chemosensitive at the time of transplant; two were refractory or had relapses. The 12-month treatment-related mortality was zero. The median follow-up was 44 months, with a 4-year disease-free survival of 43% and an OS at 4 years of 73%. The decreasing treatment-related mortality in this chemosensitive population is encouraging, and again, the fraction of patients who were relapse free beyond 4 years suggests that this technique is valuable.
One hundred and fifty-eight adult patients with Waldenströ m were reported to the European Group for Blood and Marrow Transplantation between January 1991 and December 2005. 49 Thirty-two percent of the patients had treatment failure with three lines of prior therapy, but 93% were chemotherapy sensitive at the time of transplant. Forty-five patients had TBI-based conditioning. The median survival of surviving patients was 4.2 years. The nonrelapse mortality at 1 year was a respectable 3.8%, although a secondary malignancy developed in 10 patients, with an incidence of 8.4% at 5 years. The relapse rate at 5 years was 52.1%, PFS at 5 years was 39.7% and OS at 5 years was 68.5% and depended on the number of lines of prior chemotherapy and whether the patients were chemorefractory at the time of autologous stem cell transplant. The achievement of negative immunofixation after stem cell transplant had a positive impact on survival. When used as consolidation at first response, the PFS was 44% at 5 years. Forty-six percent of patients received a BEAM protocol; 94% had peripheral blood stem cells as their source; 93% were chemosensitive at the time of transplant. Autologous stem cell transplant can be performed with low treatment-related mortality, and responses often last 4--5 years, with little or no toxicity after the first 120 days. The technique is unlikely to be of benefit to those patients with chemotherapy-resistant disease and those for whom three courses of therapy failed.
The outcomes in the largest series of autologous transplants are summarized in Table 2 .
ALLOGENEIC STEM CELL TRANSPLANT
Single-center experience The first reports of allogeneic transplant were limited to case reports, as they were for patients receiving autologous transplants. Two patients with aggressive Waldenströ m had disease progression despite multiagent chemotherapy and autologous stem cell transplant in 1. 50 They both underwent allogeneic transplants from an HLA-identical donor. Both were alive and event free 3 and 9 years, respectively. These were younger patients, and allogeneic transplant at that point in their disease course (advanced) was recommended for consideration.
A 62-year-old man underwent nonmyeloablative allogeneic stem cell transplant because of severe pancytopenia associated with refractory Waldenströ m. 51 Mixed chimerism was achieved and became completely donor derived after an episode of GVHD.
Three allogeneic transplants were reported from MD Anderson Cancer Center. 40 One patient died of GVHD on post transplant day 39. One patient had a partial response, and one patient had an EFS of 20 months and an OS longer than 2 years.
A retrospective study of allogeneic stem cell transplant in five patients with Waldenströ m was reported. 52 A combination of BU and CY was used for all, and CsA and MTX were administered for graft-vs-host prophylaxis. With a median of 32 months of followup, four of the five were alive and disease free. There was a decline in serum IgM levels in all patients, suggesting an active graft-vsWaldenströ m effect.
Meniane et al. 53 reported a 52-year-old man fulfilling the diagnostic criteria of Waldenströ m macroglobulinemia treated with six courses of CHOP chemotherapy with no response. Second-line chemotherapy included fludarabine and CY with a 70% reduction in the IgM component followed by a reducedintensity conditioning with fludarabine, BU and antithymocyte globulin followed by allogeneic stem cell transplant from his HLAmatched sister. There was no GVHD and no significant clinical response, so donor lymphocyte infusion was performed and resulted in conversion to full-donor chimerism. This led to an immunofixation-negative complete response at 28 months, with moderate limited chronic GVHD and a Karnofsky score of 100%. 53 Allogeneic transplant has also been applied in a Waldenströ m patient, who developed transformation to a large cell B-cell lymphoma. A complete response was achieved with an allogeneic transplant after reduced-intensity conditioning. 54 Registry and cooperative group experience A systematic review published in 2003 identified six patients, with a median age of 45 years, who received allogeneic stem cell transplants. 55 All were heavily pretreated and had refractory or relapsed disease. Median time from diagnosis to transplant was 3.1 years. Two of the six patients died of treatment-related causes.
One of the six patients died of disease progression. Three were alive and well between 5 and 112 months after transplant. No conclusions can be drawn from such a small cohort other than the feasibility of treatment, but these outcomes do point out the potential for high treatment-related mortality. The French experience using allogeneic transplant in 10 patients with Waldenströ m has been reported. 44 All the transplant patients received myeloablative conditioning. Four of the patients died at 3, 11, 12 and 18 months; three patients died of microangiopathic hemolytic anemia. All deaths were considered treatment related. Chronic GVHD led to the death of one patient. Six patients are alive at 3, 23, 50, 59, 74 and 76 months. The overall treatment-related mortality was 40%.
In an abstract presented at the International Workshop on Waldenströ m Macroglobulinemia in 2006, 11 patients received allogeneic transplants after myeloablative conditioning, and 11 received allogeneic transplants after reduced-intensity conditioning. 47 Relapse was seen in 4 of the 11 myeloablative patients and in none of the 11 reduced-intensity allogeneic patients. The median EFS was 36 months in the patients receiving myeloablative transplants and has not been reached in reduced-intensity patients. The 1-, 3-and 5-year OS in the myeloablative group was 64, 54 and 54%. In the patients who received reduced-intensity allogeneic transplants, it was 82, 68 and 68%. TRM was 36% for myeloablative transplants and 27% with reduced-intensity transplants, suggesting reduced intensity is safer and has similar outcomes. Nonmyeloablative allogeneic transplant produces impressive results in older patients (median age, 56 years), longterm disease control and survivals as long as 149 months.
Allogeneic transplants in 26 patients from the Center for International Blood and Marrow Transplant Research were reported retrospectively. 45 Fifty-eight percent of the patients received myeloablative conditioning including TBI. Nineteen percent received nonmyeloablative, reduced-intensity conditioning. After a median follow-up of 65 months, 9 of the 26 allogeneic patients (35%) were alive. Relapse of Waldenströ m accounted for 29% of the deaths in the allogeneic group. The relapse rate at 3 years was 29% for allogeneic recipients. PFS at 3 years was 31%. OS was 46% at 3 years. Nonrelapse mortality at 3 years was 40%. Allogeneic transplant after ablative conditioning carried a very high risk of nonrelapse mortality---40%---and allogeneic transplant should be used sparingly.
Meniane et al. 53 reviewed reports describing 46 patients; 12 received transplants after reduced-intensity conditioning and 34 had transplants after myeloablative conditioning. At the time of the summary of the 20 reported individual patients, only 7 had died. Of the 26 reported in aggregate, survival was 46% at 3 years, and treatment-related mortality was 40%.
The British Society of Bone and Marrow Transplantation reported the outcomes of nine patients who received allografts---HLA-matched sibling stem cells in eight patients and unrelated stem cells in one patient. 48 Two patients received TBI, two had BEAM conditioning and five received fludarabine and melphalan. Seven were chemosensitive at the time of transplant. Two had primary refractory disease. The treatment-related mortality at 12 months was 44% and included graft failure and GVHD, both acute and chronic. With a median follow-up of 32 months, the 4-year disease-free survival was 44%, and the OS is 56%.
Recently, Garnier et al. 56 reported on 25 patients from a database, all of whom received allogeneic transplants for Waldenströ m macroglobulinemia. The median age was 48 years, and the oldest patient was 64 years. There was a median of three prior lines of therapy (44% had refractory disease) at the time of transplant. The transplant was done after myeloablative conditioning in 11, and 13 had reduced-intensity conditioning. The overall response rate was 92%. Complete responses were obtained in 50% of evaluable patients. With a median follow-up of 64 months among survivors, the 5-year overall and PFSs were 67 and 58%, respectively. Only one relapse occurred among the 12 patients who entered CR. Only one of six relapses occurred 43 years after transplant. Allogeneic stem cell transplants yielded a high rate of complete responses and are potentially curative in poor-risk patients with Waldenströ m. The European Bone Marrow Transplant Registry contained 86 patients with Waldenströ m receiving an allograft; the transplant was fully myeloablative in 37 patients, and 49 patients had reduced-intensity conditioning. 57 The median age of the patients was 49 years. Eight patients had disease progression after a previous autologous stem cell transplant; 68.6% were chemotherapy sensitive at the time of allogeneic transplant and the median follow-up of survivors was 50 months. Nonrelapse mortality at 3 years was 33% for patients who had myeloablative conditioning and 23% for those who had reduced-intensity conditioning. The overall response rate was 75.6%. The 3-year relapse rate was 11% for myeloablative transplants and 25% for reduced-intensity transplants. Fourteen patients received donor lymphocyte infusions for disease relapse. Five-year PFS and OS were 56 and 62%, respectively, for myeloablative transplants, and 49 and 64%, respectively, for reduced-intensity transplants. Chronic GVHD was associated with higher nonrelapse mortality and a lower relapse rate, leading to the improved PFS. Allogeneic stem cell transplant can induce durable remissions in heavily pretreated patients. The low relapse rate in patients developing chronic GVHD suggests the existence of a clinically relevant graft-vs-Waldenströ m macroglobulinemia effect.
The largest series of allogeneic transplants are summarized in Table 3 .
MAYO CLINIC'S INTERPRETATION OF THE DATA ON STEM CELL TRANSPLANT FOR WALDENSTRÖ M MACROGLOBULINEMIA
It appears that autologous transplant can be performed for Waldenströ m macroglobulinemia with a very low nonrelapse mortality in patients as old as 75 years. Stem cell collection after extensive prior therapy is a challenge and should not be delayed until patients have received three prior lines of therapy. These therapeutic regimens often contain purine nucleoside analogs that can impair the mobilization of stem cells or extensive exposure to alkylating agents that can cause chromosomal damage and lead to myelodysplasia. We do not believe, given the excellent outcomes with standard induction chemotherapy, that autologous transplant can be recommended as first-line therapy for Waldenströ m macroglobulinemia. However, we do believe in the concept of 'rainy day' collection after patients have achieved first response, and a minimal tumor mass would allow effective collection of stem cells without the need for mobilizing chemotherapy or plerixafor. These cells can be cryopreserved for use at the time of first progression. It is a reasonable expectation that autologous transplant can be performed in patients with relapsed disease without testing for chemotherapy sensitivity, as is required in intermediate-grade lymphomas. Median relapse-free survival of 3.5--4 years would be expected on the basis of published series, and this could be achieved at a cost lower than that associated with salvage therapies with novel agents, including bortezomib and bendamustine. Therefore, we believe that it is appropriate for patients in first plateau who are under the age of 70 years to be considered for collection and storage of stem cells for future use. Allogeneic transplant carries treatment-related mortality of 15--40%, and its use as second-line therapy in patients who have many chemotherapeutic options is not appropriate. However, there are patients whose options for use of conventional chemotherapy may have been exhausted and for whom collection of autologous stem cells is not an option. In patients with multiresistant disease, the option of the infusion of allogeneic stem cells with nonmyeloablative conditioning may be justified when the individual patient's alternatives are limited. Ideally, this treatment should be done in the context of a clinical trial. In Waldenströ m macroglobulinemia, given its rarity, clinical trials may not always be available. 
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